Dr. Reddy's Lab


Concise Prescribing Info
Monotherapy or in combination w/ ribociclib, abemaciclib or palbociclib for estrogen-receptor positive human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated w/ endocrine therapy; locally advanced or metastatic breast cancer in postmenopausal women w/ disease relapse on or after adjuvant endocrine therapy, or disease progression on endocrine therapy.
Dosage/Direction for Use
Adult female including elderly 500 mg at 1-mth intervals w/ additional 500-mg dose given 2 wk after initial dose, administered 1 in each buttock as 2 consecutive 5 mL slow IM inj.
Hypersensitivity. Severe hepatic impairment. Pregnancy & lactation.
Special Precautions
Bleeding diatheses, thrombocytopenia; thromboembolic events; potential risk of osteoporosis. Dorsogluteal inj site due to proximity of underlying sciatic nerve. Interfered Ab-based estradiol assays. Concomitant use w/ anticoagulants. May affect ability to drive & use machines. Mild to moderate hepatic impairment. Severe renal impairment (CrCl <30 mL/min). Women of childbearing potential should use effective contraception. Not to be used during pregnancy & lactation. Not to be used in neonates. Avoid use in childn <2 yr. Not recommended in childn or adolescents.
Adverse Reactions
Hypersensitivity reactions; hot flushes; nausea; elevated hepatic enzymes; rash; joint & musculoskeletal pain; asthenia, inj site reactions. UTI; reduced platelet count; anorexia; headache; venous thromboembolism; vomiting, diarrhoea; elevated bilirubin; back pain; vag haemorrhage; sciatica, peripheral neuropathy.
MIMS Class
Cancer Hormone Therapy
ATC Classification
L02BA03 - fulvestrant ; Belongs to the class of anti-estrogens. Used in treatment of neoplastic diseases.
Eranfu soln for inj 250 mg/5 mL
2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in